Arnold Christoph Reinhold, Mangesius Julian, Skvortsova Ira-Ida, Ganswindt Ute
Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
EXTRO-Lab, Tyrolean Cancer Research Institute, Innsbruck, Austria.
Front Oncol. 2020 Feb 20;10:164. doi: 10.3389/fonc.2020.00164. eCollection 2020.
Cancer stem cells (CSC) are a distinct subpopulation within a tumor. They are able to self-renew and differentiate and possess a high capability to repair DNA damage, exhibit low levels of reactive oxygen species (ROS), and proliferate slowly. These features render CSC resistant to various therapies, including radiation therapy (RT). Eradication of all CSC is a requirement for an effective antineoplastic treatment and is therefore of utmost importance for the patient. This makes CSC the prime targets for any therapeutic approach. Albeit clinical data is still scarce, experimental data and first clinical trials give hope that CSC-targeted treatment has the potential to improve antineoplastic therapies, especially for tumors that are known to be treatment resistant, such as glioblastoma. In this review, we will discuss CSC in the context of RT, describe known mechanisms of resistance, examine the possibilities of CSC as biomarkers, and discuss possible new treatment approaches.
癌症干细胞(CSC)是肿瘤内一个独特的亚群。它们能够自我更新和分化,具有高度修复DNA损伤的能力,活性氧(ROS)水平低,增殖缓慢。这些特性使CSC对包括放射治疗(RT)在内的各种疗法具有抗性。根除所有CSC是有效抗肿瘤治疗的必要条件,因此对患者至关重要。这使得CSC成为任何治疗方法的主要靶点。尽管临床数据仍然稀缺,但实验数据和首批临床试验带来了希望,即针对CSC的治疗有可能改善抗肿瘤疗法,尤其是对于已知具有治疗抗性的肿瘤,如胶质母细胞瘤。在本综述中,我们将在放疗的背景下讨论CSC,描述已知的抗性机制,研究CSC作为生物标志物的可能性,并讨论可能的新治疗方法。